Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuanbi Antong prescription for critical coronary artery disease (phlegm-stasis-heat interjunction)
ChiCTR2400083668Phase 3Not yet recruiting
- Sponsor
- Guang'anmen Hospital
- Start
- Apr 2024
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis comparing Xuanbi Antong prescription granules with Xuanbi Antong prescription placebo (2 arms). Primary endpoint: Degree of coronary stenosis. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
Xuanbi Antong prescription granules
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2400083668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083668.